|
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, increased Ang2 levels have been documented in human cancer and cardiovascular disease (CVD), including ischemic myocardial injury, heart failure and other cardiovascular complications secondary to diabetes, chronic renal damage and hypertension.
|
31756341 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two proteins, angiopoietin-2 and thrombospondin-2, were associated with HF in 3 separate validation cohorts.
|
31047008 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical symptoms of heart failure in Balb/CJ mice gave the hypothesis that ANG II + Salt impairs cardiac function and induces cardiac remodeling in male Balb/CJ but not in male C57BL/6J mice.
|
30840486 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice with SMC ATG7 deficiency that are chronically infused with Ang II do not tend to develop dissecting AAA but do exhibit adverse aortic remodeling and appreciable cardiac failure-associated mortality.
|
29273297 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among participants with CKD, four proteins were associated with HF at Bonferroni-level significance (p<2.5x10(-4)): Angiopoietin-2 (HR[95%CI] 1.45[1.33, 1.59]), Spondin-1 (HR[95%CI] 1.13 [1.06, 1.20]), tartrate-resistant acid phosphatase type 5 (HR[95%CI] 0.65[0.53, 0.78]) and neurogenis locus notch homolog protein 1 (NOTCH1) (HR[95%CI] 0.67[0.55, 0.80]).
|
30557359 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of Angpt2 thus has potential as a therapeutic option for ischemic heart failure.
|
30295643 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the study, the rat heart failure (HF) model was established by ligating the left anterior descending coronary artery (LAD) and treated with ghrelin (100μg/kg, subcutaneous injection, bid); neonatal rat cardiomyocytes were cultured and stimulated with Ang II (0.1μM) and ghrelin(0.1μM) to explore the underlying mechanism of ghrelin in myocardial remodeling.
|
29113826 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibition of this enzyme or the blockade of the Ang II receptors demonstrated a high clinical value against the progression of HF.
|
28833476 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relatively low efficacy of ACE-inhibitors in the treatment of heart failure in women after estrogen loss may be due to their inability to reach the intracellular sites at which angiotensin (Ang) II is generated and/or the existence of cell-specific mechanisms in which ACE is not the essential processing pathway for Ang II formation.
|
28888034 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several antagonists of GPCRs, such as βARs (β-adrenergic receptors) and Ang II (angiotensin II) receptors, are now considered standard of therapy for a wide range of cardiovascular disease, such as hypertension, coronary artery disease, and heart failure.
|
30355236 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study elucidates that PDE5A is a novel direct target of miR-19a/b-3p, and demonstrates that antihypertrophic roles of the miR-19a/b-3p family in Ang II-induced hypertrophy and cardiac remodeling, suggests that endogenous miR-19a/b-3p might have clinical potential to suppress cardiac hypertrophy and heart failure.
|
29664809 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heart failure upregulates Ang-II intracrine signaling-components in atrial fibroblasts.
|
28381466 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rationale for the development and the Food and Drug Administration approval of LCZ-696 was based on the concept of an additive effect of the Ang II receptor blocker valsartan and the neutral endopeptidase (neprilysin) inhibitor AHU-377 for the treatment of hypertension and HF.
|
28652105 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The beneficial effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (ANG II) receptor antagonists in patients with heart failure secondary to reduced ejection fraction (HFrEF) are felt to result from prevention of the adverse effects of ANG II on systemic afterload and renal homeostasis.
|
28679681 |
2017 |
|
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ang-converting enzyme (ACE) 2 (ACE2) is a homolog of ACE, which, being a monocarboxypeptidase converts Ang II into Ang 1-7 and is downregulated in HF.
|
28279521 |
2017 |
|
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mas and AT1 receptor protein expressions, Ang-(1-7) and Ang II levels in CHF increased.
|
28848201 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic heart failure (CHF) increases sympathoexcitation through angiotensin II (ANG II) receptors (AT1R) in the paraventricular nucleus (PVN).
|
26699387 |
2016 |
|
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with patients with heart failure or those with orthotopic heart transplantation, serum levels and endothelial expression of Ang-2 were higher in LVAD patients (P=0.001 and P<0.001, respectively).
|
27354285 |
2016 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin-II (Ang-II) is associated with many conditions involving heart failure and pathologic hypertrophy.
|
23337087 |
2013 |
|
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with CHF, calpain upregulation was associated with an increase in cleavage of cain/cabin1 and the activation of CaN, indicating that these changes in calcium-regulated proteinases contribute to Ang II-induced cardiac remodelling.
|
20514436 |
2010 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors and Ang II receptor antagonists have been shown to be cardioprotective in experimental animal models, with ischemia-reperfusion injury and in patients with congestive heart failure.
|
9796075 |
1998 |